- Recipharm has launched ReciPredict, a platform designed to accelerate drug development by 3 to 6 months and reduce API consumption by up to 70%.
- The platform applies advanced data science, statistical tools, and material science to streamline the development and manufacturing process.
Recipharm has introduced ReciPredict, a new platform aimed at transforming the drug development and manufacturing process by leveraging a systematic Quality by Design (QbD) approach. The platform integrates material sciences, statistical modeling, and simulation to enhance the efficiency and reliability of pharmaceutical product development.
According to Recipharm, ReciPredict offers substantial benefits, including accelerating the journey of new drugs to the clinical stage by 3 to 6 months and reducing active pharmaceutical ingredient (API) consumption by 30% to 70%. Dr. Uwe Hanenberg, Head of Product Implementation, stated that the platform also mitigates risks during tech transfers by identifying optimal parameters for robust processes, ensuring consistent and high-quality results.
“ReciPredict offers an unparalleled understanding of materials and processes, enabling faster and more efficient drug development,” said Hanenberg. The platform incorporates a range of tools, including advanced data science, statistical analysis, and material characterization technologies, which collectively improve drug development, tech transfers, and manufacturing workflows.
ReciPredict can be applied across various stages of drug development, from initial formulation to process optimization. Its versatility makes it suitable for a wide range of products, sites, and technologies, providing pharmaceutical companies with an efficient solution to enhance drug development and contract manufacturing processes.
 Overview of outsourcing trends 
